NCT06546670 - A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 12, 2028

Study Completion Date

December 19, 2029

Conditions

Sickle Cell Disease

Interventions

DRUG

ITU512

ITU512 is an investigational, oral, low molecular weight (LMW) compound.

DRUG

Placebo

An inactive substance that looks like and is given the same way as ITU512. The effect(s) of ITU512 will be evaluated against the placebo. Placebos are designed as a control and to have no real effect.

Trial Locations (1)

33126

RECRUITING

Quotient Sciences Sea View, Miami